- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
IBA showcases low-cost proton therapy
Belgium-based IBA (Ion Beam Applications) is hawking its two-room proton therapy solution this week at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting as a smaller, lower-cost alternative to traditional proton therapy centers.
Belgium-based IBA (Ion Beam Applications) is hawking its two-room proton therapy solution this week at the American Society for Therapeutic Radiology and Oncology (ASTRO) meeting as a smaller, lower-cost alternative to traditional proton therapy centers. The IBA configuration, dubbed Proteus Nano, starkly contrasts the often two-story proton therapy centers that occupy as much as 100,000 square feet. The company is framing Proteus Nano as requiring a much smaller footprint and imposing a lower acquisition cost, while still providing the highly accelerated proton beams needed to kill cancer tumors.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Researchers Show Higher Breast Cancer Upstaging Rate with 18F-FAPI PET/CT
September 9th 2024The imaging agent 18F-FAPI PET/CT demonstrated greater than a 45 percent higher sensitivity rate in comparison to 18F-FDG PET/CT for the detection of axillary and extraaxillary regional lymph node metastases, according to a lesion-based analysis from a recent study.
